Multispectral singlet oxygen and photosensitizer luminescence dosimeter for continuous photodynamic therapy dose assessment during treatment.
| Title: | Multispectral singlet oxygen and photosensitizer luminescence dosimeter for continuous photodynamic therapy dose assessment during treatment. |
|---|---|
| Authors: | Moritz TJ; Physical Sciences Inc., Andover, Massachusetts, United States.; Zhao Y; Physical Sciences Inc., Andover, Massachusetts, United States.; Hinds MF; Physical Sciences Inc., Andover, Massachusetts, United States.; Gunn JR; Thayer School of Engineering at Dartmouth, Hanover, New Hampshire, United States.; Shell JR; Thayer School of Engineering at Dartmouth, Hanover, New Hampshire, United States.; Pogue BW; Thayer School of Engineering at Dartmouth, Hanover, New Hampshire, United States.; Davis SJ; Physical Sciences Inc., Andover, Massachusetts, United States. |
| Source: | Journal of biomedical optics [J Biomed Opt] 2020 Mar; Vol. 25 (6), pp. 1-13. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Language: | English |
| Journal Info: | Publisher: Published by SPIE--the International Society for Optical Engineering in cooperation with International Biomedical Optics Society Country of Publication: United States NLM ID: 9605853 Publication Model: Print Cited Medium: Internet ISSN: 1560-2281 (Electronic) Linking ISSN: 10833668 NLM ISO Abbreviation: J Biomed Opt Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Bellingham, WA : Published by SPIE--the International Society for Optical Engineering in cooperation with International Biomedical Optics Society, c1996- |
| MeSH Terms: | Photosensitizing Agents*/therapeutic use ; Photochemotherapy*; Animals ; Humans ; Luminescence ; Mice ; Radiation Dosimeters ; Singlet Oxygen |
| Abstract: | Significance: Photodynamic therapy (PDT) involves complex light-drug-pathophysiology interactions that can be affected by multiple parameters and often leads to large variations in treatment outcome from patient to patient. Direct PDT dosimetry technologies have been sought to optimize the control variables (e.g., light dose, drug administration, tissue oxygenation, and patient conditioning) for best patient outcomes. In comparison, singlet oxygen (O21) dosimetry has been tested in various forms to provide an accurate and perhaps comprehensive prediction of the treatment efficacy.; Aim: We discuss an advanced version of this approach provided by a noninvasive, continuous wave dosimeter that can measure near-infrared spectrally resolved luminescence of both photosensitizer (PS) and O21 generated during PDT cancer treatment.; Approach: This dosimetry technology uses an amplified, high quantum efficiency InGaAs detector with spectroscopic decomposition during the light treatment to continuously extract the maximum signal of O21 phosphorescence while suppressing the strong PS luminescence background by spectrally fitting the data points across nine narrow band wavelengths. O21 and PS luminescence signals were measured in vivo in FaDu xenograft tumors grown in mice during PDT treatment using Verteporfin as the PS and a continuous laser treatment at 690 nm wavelength.; Results: A cohort of 19 mice was used and observations indicate that the tumor growth rate inhibition showed a stronger correlation with O21 than with just the PS signal.; Conclusions: These results suggest that O21 measurement may be a more direct dosimeter of PDT damage, and it has potential value as a definitive diagnostic for PDT treatment, especially with spectral separation of the background luminescence and online estimation of the PS concentration. |
| References: | Br J Cancer. 2016 Sep 27;115(7):805-13. (PMID: 27575852); Cancer. 1972 Jan;29(1):117-21. (PMID: 4332311); Cancer Med. 2015 May;4(5):633-42. (PMID: 25712788); Cancer Res. 2003 Nov 15;63(22):7986-94. (PMID: 14633731); J Biomed Opt. 2008 Nov-Dec;13(6):064035. (PMID: 19123681); Phys Med Biol. 2016 Apr 7;61(7):R57-89. (PMID: 26961864); Anticancer Res. 2003 Jan-Feb;23(1B):505-22. (PMID: 12680139); Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):917-23. (PMID: 16467106); Br J Cancer. 2005 Jan 31;92(2):298-304. (PMID: 15655542); Photochem Photobiol. 2002 Apr;75(4):382-91. (PMID: 12003128); J Biomed Opt. 2017 Feb 1;22(2):28002. (PMID: 28301655); J Biomed Opt. 2014 Feb;19(2):028001. (PMID: 24503639); Can J Gastroenterol. 2002 Jun;16(6):393-6. (PMID: 12096303); Proc SPIE Int Soc Opt Eng. 2019 Feb;10860:. (PMID: 31327886); J Natl Cancer Inst. 1998 Jun 17;90(12):889-905. (PMID: 9637138); J Photochem Photobiol B. 2016 Jun;159:14-23. (PMID: 26995671); Nat Rev Cancer. 2003 May;3(5):380-7. (PMID: 12724736); Cancer Res. 2004 Oct 15;64(20):7553-61. (PMID: 15492282); J Photochem Photobiol B. 1997 May;39(1):1-18. (PMID: 9210318); Biophys J. 2012 Feb 8;102(3):661-71. (PMID: 22325290); Cancer Res. 1992 Sep 15;52(18):4914-21. (PMID: 1387584); J Biomed Opt. 2008 Sep-Oct;13(5):050504. (PMID: 19021376); Proc SPIE Int Soc Opt Eng. 2016 Feb 13;9694:. (PMID: 27053822); Biomed Opt Express. 2011 Apr 15;2(5):1233-42. (PMID: 21559134); Photochem Photobiol. 2018 Mar;94(2):213-218. (PMID: 29143339); Appl Opt. 1998 Nov 1;37(31):7168-83. (PMID: 18301543); Photodiagnosis Photodyn Ther. 2017 Sep;19:298-303. (PMID: 28750754); J Biomed Opt. 2016 Aug 1;21(8):88002. (PMID: 27552311); Photochem Photobiol. 2007 May-Jun;83(3):738-48. (PMID: 17576383); Mol Cancer Ther. 2017 Jun;16(6):1092-1101. (PMID: 28336806); Cancer Res. 2003 Mar 1;63(5):1025-33. (PMID: 12615718); Cancer Res. 2016 Mar 1;76(5):1066-77. (PMID: 26719532); J Biophotonics. 2016 Dec;9(11-12):1314-1325. (PMID: 27136270); Proc SPIE Int Soc Opt Eng. 2016 Feb 13;9694:. (PMID: 27064489); J Biophotonics. 2010 Jun;3(5-6):304-18. (PMID: 20222102) |
| Grant Information: | P01 CA084203 United States CA NCI NIH HHS; P30 CA023108 United States CA NCI NIH HHS; R44 CA213607 United States CA NCI NIH HHS |
| Contributed Indexing: | Keywords: dose; photodynamic therapy; singlet oxygen; spectroscopy; tumor regrowth |
| Substance Nomenclature: | 0 (Photosensitizing Agents); 17778-80-2 (Singlet Oxygen) |
| Entry Date(s): | Date Created: 20200315 Date Completed: 20210924 Latest Revision: 20210924 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7068220 |
| DOI: | 10.1117/1.JBO.25.6.063810 |
| PMID: | 32170859 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural